{"schema_version":"secwatch.filing_event.v1","accession":"0001818331-24-000057","form_type":"8-K","ticker":"WGS","cik":"0001818331","company_name":"GeneDx Holdings Corp.","filed_at":"2024-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.806632+00:00","generated_at":"2026-05-30T09:22:33.587591+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"GeneDx achieves Q3 2024 profitability with $1.2M adjusted net income, raises FY guidance","bullets":["Revenue $76.6M (+52% YoY); exome/genome revenue $60.0M (+77% YoY).","Adjusted net income $1.2M (first profitable quarter); GAAP net loss $8.3M.","Adjusted gross margin 64%, up from 48% YoY.","FY 2024 revenue guidance raised to $284–290M (prev. $255–265M).","Cash use improved 88% YoY to $5.0M; $117.4M cash as of Sept. 30, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001818331-24-000057","json":"https://secwatch.observer/filing/0001818331-24-000057.json","markdown":"https://secwatch.observer/filing/0001818331-24-000057.md","text":"https://secwatch.observer/filing/0001818331-24-000057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818331/000181833124000057/0001818331-24-000057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818331/000181833124000057/wgs-20241029.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T09:22:33.587591+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}